147 related articles for article (PubMed ID: 9971797)
1. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.
Martiney MJ; Levy LS; Lenz J
J Virol; 1999 Mar; 73(3):2143-52. PubMed ID: 9971797
[TBL] [Abstract][Full Text] [Related]
2. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
Martiney MJ; Rulli K; Beaty R; Levy LS; Lenz J
J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
[TBL] [Abstract][Full Text] [Related]
3. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.
Amtoft HW; Sørensen AB; Bareil C; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Jul; 71(7):5080-7. PubMed ID: 9188573
[TBL] [Abstract][Full Text] [Related]
4. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
Zaiman AL; Nieves A; Lenz J
J Virol; 1998 Apr; 72(4):3129-37. PubMed ID: 9525638
[TBL] [Abstract][Full Text] [Related]
5. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
Ethelberg S; Lovmand J; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.
Zaiman AL; Lewis AF; Crute BE; Speck NA; Lenz J
J Virol; 1995 May; 69(5):2898-906. PubMed ID: 7707514
[TBL] [Abstract][Full Text] [Related]
7. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.
Morrison HL; Soni B; Lenz J
J Virol; 1995 Jan; 69(1):446-55. PubMed ID: 7983741
[TBL] [Abstract][Full Text] [Related]
8. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.
Ethelberg S; Hallberg B; Lovmand J; Schmidt J; Luz A; Grundström T; Pedersen FS
J Virol; 1997 Feb; 71(2):1196-206. PubMed ID: 8995642
[TBL] [Abstract][Full Text] [Related]
9. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.
Nieves A; Levy LS; Lenz J
J Virol; 1997 Feb; 71(2):1213-9. PubMed ID: 8995644
[TBL] [Abstract][Full Text] [Related]
10. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
Sørensen KD; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.
Zaiman AL; Lenz J
J Virol; 1996 Aug; 70(8):5618-29. PubMed ID: 8764076
[TBL] [Abstract][Full Text] [Related]
12. The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity.
Pantginis J; Beaty RM; Levy LS; Lenz J
J Virol; 1997 Dec; 71(12):9786-91. PubMed ID: 9371646
[TBL] [Abstract][Full Text] [Related]
13. Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells.
LoSardo JE; Cupelli LA; Short MK; Berman JW; Lenz J
J Virol; 1989 Mar; 63(3):1087-94. PubMed ID: 2644446
[TBL] [Abstract][Full Text] [Related]
14. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
Ethelberg S; Tzschaschel BD; Luz A; Diaz-Cano SJ; Pedersen FS; Schmidt J
J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
[TBL] [Abstract][Full Text] [Related]
15. Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1.
Mertz JA; Mustafa F; Meyers S; Dudley JP
J Virol; 2001 Mar; 75(5):2174-84. PubMed ID: 11160721
[TBL] [Abstract][Full Text] [Related]
16. B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.
Lovmand J; Sorensen AB; Schmidt J; Ostergaard M; Luz A; Pedersen FS
J Virol; 1998 Jul; 72(7):5745-56. PubMed ID: 9621033
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the significance of two single-base-pair differences in the SL3-3 and Akv virus long terminal repeats.
Morrison HL; Dai HY; Pedersen FS; Lenz J
J Virol; 1991 Feb; 65(2):1019-22. PubMed ID: 1846181
[TBL] [Abstract][Full Text] [Related]
18. Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.
Boral AL; Okenquist SA; Lenz J
J Virol; 1989 Jan; 63(1):76-84. PubMed ID: 2535754
[TBL] [Abstract][Full Text] [Related]
19. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells.
Nuchprayoon I; Meyers S; Scott LM; Suzow J; Hiebert S; Friedman AD
Mol Cell Biol; 1994 Aug; 14(8):5558-68. PubMed ID: 8035830
[TBL] [Abstract][Full Text] [Related]
20. An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo.
Ethelberg S; Sørensen AB; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Dec; 71(12):9796-9. PubMed ID: 9371648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
